As of 4:00pm ET
| -0.08 / -2.03%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +93.80% increase from the last price of 3.87.
The current consensus among 2 polled investment analysts is to Outperform stock in Novelion Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.